Evolus Inc. (EOLS)
Evolus Inc. (EOLS) Stock Price, Analysis & Data
| Bid | 4.47 |
| Market Cap | 539.63M |
| Revenue (ttm) | 316.49M |
| Net Income (ttm) | -34.33M |
| Beta | 1.36 |
| EPS (ttm) | -0.53 |
| PE Ratio (ttm) | n/a |
| Forward PE | 31.67 |
| P/B (ttm) | -17.46 |
| P/S (ttm) | 1.71 |
| Earnings Date | Nov 4, 2026 |
| Ask | 7.82 |
| Volume | 403,317 |
| Avg. Volume (20D) | 839,070 |
| Open | 8.25 |
| Previous Close | 8.34 |
| Day's Range | 8.11 - 8.35 |
| 52-Week Range | 3.86 - 8.43 |
| Analyst | Strong Buy |
| Price Target | 14 (71.36%) |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About EOLS
Evolus, Inc., a performance beauty company, delivers products in the cash-pay aesthetic market in the United States, Canada, Europe, and Australia. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults; and Evolysse, a collection of injectable hyaluronic acid gels, which includes various products, such as mid face,...
Financial Performance
In 2025, Evolus's revenue was 297.18M, an increase of 11.61% compared to the previous year's 266.27M. Earnings were -51.64M, an increase of 2.42%.
Financial StatementsAnalyst Forecast
According to 6 analyst ratings, the average rating for EOLS stock is "Strong Buy". The 12-month stock price forecast is 14, which is upside of 71.36% from the latest price.
Stock ForecastsEarnings Surprise
Analysts project revenue of ... Upgrade
2 months ago · Simply Wall St.
3 High-Growth Insider-Owned Companies With Earnings Surging Up To 80%Over the last 7 days, the United States market has risen by 1.1%, contributing to an impressive 27% climb over the past year, with earnings forecasted to grow by 17% annually. In this thriving environ...